New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - imatinib mesilate 119.5mg equivalent to imatinib 100 mg - film coated tablet - 100 mg - active: imatinib mesilate 119.5mg equivalent to imatinib 100 mg excipient: colloidal silicon dioxide crospovidone hyprolose hypromellose iron oxide red iron oxide yellow macrogol 8000 magnesium stearate - treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive chronic myeloid leukaemia (ph+cml). treatment of adult and paediatic patients with ph+cml in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy.

Canada - English - Health Canada

teva canada limited - imatinib (imatinib mesylate) - tablet - 100mg - imatinib (imatinib mesylate) 100mg - antineoplastic agents

Canada - English - Health Canada

accord healthcare inc - imatinib (imatinib mesylate) - tablet - 100mg - imatinib (imatinib mesylate) 100mg - antineoplastic agents

Canada - English - Health Canada

mint pharmaceuticals inc - imatinib (imatinib mesylate) - tablet - 100mg - imatinib (imatinib mesylate) 100mg - antineoplastic agents

Canada - English - Health Canada

apotex inc - imatinib (imatinib mesylate) - tablet - 100mg - imatinib (imatinib mesylate) 100mg - antineoplastic agents

Canada - English - Health Canada

natco pharma (canada) inc - imatinib (imatinib mesylate) - tablet - 100mg - imatinib (imatinib mesylate) 100mg - antineoplastic agents

Canada - English - Health Canada

sun pharma canada inc - imatinib (imatinib mesylate) - tablet - 100mg - imatinib (imatinib mesylate) 100mg - antineoplastic agents

Canada - English - Health Canada

pharmascience inc - imatinib (imatinib mesylate) - tablet - 100mg - imatinib (imatinib mesylate) 100mg - antineoplastic agents

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - imatinib mesilate 119.47mg equivalent to imatinib 100 mg;   - capsule - 100 mg - active: imatinib mesilate 119.47mg equivalent to imatinib 100 mg   excipient: crospovidone gelatin iron oxide red iron oxide yellow lactose monohydrate magnesium stearate titanium dioxide - treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive chronic myeloid leukaemia (ph+cml). treatment of adult and paediatic patients with ph+cml in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - imatinib mesilate, quantity: 119.469 mg (equivalent: imatinib, qty 100 mg) - tablet, film coated - excipient ingredients: calcium hydrogen phosphate; crospovidone; magnesium stearate; purified water; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; macrogol 4000; polyvinyl alcohol - 1) imatinib-teva (imatinib) is indicated for the treatment of patients with chronic myeloid leukaemia (cml). 2) imatinib-teva (imatinib) is indicated for the treatment of adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. 3) imatinib-teva (imatinib) is indicated for the treatment of adult patients with relapsed or refractory ph+all as monotherapy. 4) imatinib-teva (imatinib) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene rearrangements, where conventional therapies have failed. 5) imatinib-teva (imatinib) is indicated for the treatment of adult patients with aggressive systemic mastocytosis (asm), where conventional therapies have failed. 6) imatinib-teva (imatinib) is indicated for the treatment of adult patients with hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel). 7) imatinib-teva (imatinib) is indicated for the treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist) 8) imatinib-teva (imatinib) is indicated for the adjuvant treatment of adult patients at high risk of recurrence following complete gross resection of kit (cd117)-positive primary gist. 9) imatinib-teva (imatinib) is indicated for the treatment of adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (dfsp).